Background: Rituximab may improve transplant outcomes but may delay immunologic recovery. Patients and methods: Seventy-seven patients with low-grade or mantle cell lymphoma received autologous stemcell transplantation (ASCT) on a phase II study. Rituximab 375 mg/m 2 was administered 3 days before mobilizationdose cyclophosphamide, then weekly for four doses after count recovery from ASCT. Immune reconstitution was assessed.
introduction High-dose therapy with autologous stem-cell transplantation (ASCT) for low-grade or mantle cell lymphoma can prolong event-free survival (EFS) [1] [2] [3] [4] [5] . Nevertheless, most studies have not demonstrated an overall survival (OS) advantage [2, 5, 6] and the majority of patients relapse. Since both persistence of neoplastic cells despite high-dose therapy and their reintroduction appear to be important causes of relapse [7] , strategies are needed to address both problems.
Given its activity, minimal toxicity, and lack of crossresistance with chemotherapy, rituximab is an attractive candidate for incorporation into ASCT regimens. Administering a tumor-specific mAb before stem-cell collection may reduce the number of lymphoma cells contaminating the peripheral blood and marrow, in effect purging the stem-cell graft in vivo. Administering an antibody after transplantation at a time of minimal residual disease may augment the antitumor effect. Studies using rituximab as an in vivo purging agent have reported the ability to render a graft free of PCRdetectable tumor cells [8] [9] [10] , without impairing stem-cell collection or engraftment [10, 11] . Clinical trials of posttransplantation rituximab indicate that it may increase efficacy without prohibitive toxic effects [10, 12] . However, concerns about hypogammaglobulinemia and infection risk have been raised.
We report encouraging long-term outcomes of a phase II study undertaken to evaluate ASCT with rituximab administered as both an in vivo purging agent and a posttransplantation adjuvant for low-grade, transformed, and mantle cell lymphomas. The impact of this approach on hematopoietic recovery and infection rates is assessed.
patients and methods
eligibility From 1999 to 2002, 86 patients were enrolled in a single-institution phase II study at Johns Hopkins (J9863). The study was approved by the Johns Hopkins Institutional Review Board, and all participants gave written informed consent. Eligible diagnoses (translated from the Revised European-American Lymphoma to the World Health Organization classification) included biopsy-proven follicular lymphoma grades 1-3, chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), lymphoplasmacytic lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Outcomes for mantle cell lymphoma were included in a previous report [13] . Transformed lymphomas were not excluded. Additional eligibility requirements included age ‡18 years, Eastern Cooperative Oncology Group performance status of zero or one, no more than 10% bone marrow involvement by lymphoma, absence of active infection, creatinine level £2.0 mg/dl, bilirubin level £2.0 mg/dl unless tumor related, white blood cell count ‡3000/ll, platelet count ‡100 000/ll, and adequate cardiac and pulmonary function.
stem-cell mobilization and processing
Patients received rituximab 375 mg/m 2 i.v., followed 3 days later by cyclophosphamide 2.5 g/m 2 i.v. over 1 h with mesna (500 mg/m 2 i.v. at 3, 6, and 8 h after cyclophosphamide). Sargramostim (granulocyte-macrophage colony-stimulating factor) 250 lg/m 2 /day was administered s.c. for 7 days starting on the day after cyclophosphamide. Filgrastim (granulocyte colonystimulating factor) 10 lg/kg/day was administered starting on the sixth day after cyclophosphamide and continuing until leukapheresis. A 2-6 h leukapheresis was carried out once the peripheral blood absolute CD34+ count was >10/ll as measured by flow cytometry. Stem-cell products containing ‡5 · 10 6 CD34+ cells/kg were positively selected for CD34+ cells using the IsolexÒ system (Nexell Therapeutics, Inc., Irvine, CA). A minimum of 2 · 10 6 CD34+ cells/kg was required for transplantation. One patient with fewer CD34+ cells after positive selection was transplanted and therefore included. Nine patients did not receive peripheral blood ASCT because of inadequate stem-cell mobilization, leaving 77 patients for analysis.
high-dose therapy and posttransplant immunotherapy
The preparative regimen consisted of either cyclophosphamide (50 mg/kg/ day i.v. for 4 days) and total body irradiation (TBI; 300 cGy/day for 4 days) or busulfan (16 mg/kg orally over 4 days, with pharmacokinetic adjustments) [14] and cyclophosphamide (50 mg/kg/day i.v. for 4 days) [15] . All dosing was on the basis of ideal body weight or actual, whichever was less. Busulfan-cyclophosphamide was initially given in those unable to receive TBI and later became the institutional standard. The autograft was infused on the day after TBI or cyclophosphamide, (day 0). Four additional weekly doses of rituximab 375 mg/m 2 i.v. were administered after the absolute neutrophil count (ANC) was ‡1000/ll for 3 days and the unsupported platelet count was ‡20 000/ll for 7 days. Five patients did not receive or complete posttransplantation rituximab because of medical contraindications or patient preference. For the theoretical capacity to potentiate the effects of rituximab [16] , sargramostim (250 lg/m 2 /day s.c. until ANC >1000/ll for 3 days, then 125 lg/m 2 /day, adjusted for leukocytosis or toxic effects) was begun on day 1 and continued for 1 week after the last dose of rituximab. Antibiotic prophylaxis and supportive care were delivered according to standard practice [10] .
follow-up assessments
Patients were evaluated at 60 days, 6 months, and 1 year posttransplantation and generally annually thereafter at Johns Hopkins. Interim quarterly assessments by their primary hematologist/oncologist were recommended. Late-onset neutropenia (ANC <1000/ll) occurring after documented recovery from a first episode of neutropenia was regarded as a second episode. Quantitative immunoglobulins and peripheral blood lymphocyte counts were drawn at baseline (before mobilization therapy) and in a subset of patients, serially posttransplantation until relapse. A minority of values were obtained at outside laboratories. For quantitative immunoglobulin values reported as less than a lower limit, the average of zero and the lower limit was substituted for analytical purposes. Lymphocyte subsets were quantified by multicolor flow cytometry, with a single platform method used for CD3, CD4, and CD8 quantification. For lymphocyte counts other than CD4, an absolute lymphocyte count was calculated using the absolute and percentage CD4, then multiplied by the percentage of other subsets. Natural killer (NK) cells were defined as CD45+, CD32, CD56+, and CD16+ events. B cells were CD45+, CD32, and CD19+.
statistical methods EFS and OS were estimated using the Kaplan-Meier method and were measured from date of ASCT. An event was defined as relapse or progression, diagnosis of myelodysplastic syndrome (MDS) or acute leukemia, or death from any cause. For patients without clinical evidence of progression, radiographic confirmation of freedom from progressive lymphoma was required. Cumulative incidence of progression or relapse was estimated using a competing risks analysis, where nonrelapse deaths and secondary hematologic cancers were competing risks [17] . Univariate Cox proportional hazards models were used to determinate associations between clinical variables and EFS. Variables with a P <0.10 were then included in a multivariate Cox model. A hazard ratio >1 indicates the increased risk of failure associated with having the variable relative to its reference. Posttransplantation lymphocyte and immunoglobulin values, when evaluated as a proportion of baseline values, were summarized using geometric means. t-tests were used on log scale proportions to test for significant changes from baseline. All P values are two-sided. Statistical analyses were carried out with R, version 2.8.0 [18] and represent data through 6 February 2009.
results disease and survival outcomes
The characteristics of the 77 transplanted patients are shown in Table 1 . Thirty-two patients (42%) had follicular lymphoma (including six with large-cell transformation), with the other most common diagnoses being mantle cell lymphoma (25%) and CLL/SLL (16%). Sixty percent of transplants were carried out in first remission, with similar numbers of patients receiving busulfan-cyclophosphamide and cyclophosphamide-TBI conditioning.
With a median follow-up of 4.5 years (range 0.3-9.9 years) for all patients and 6.2 years in those without events, the actuarial EFS at 5 years and 8 years after ASCT is 60% [95% confidence interval (CI) 50% to 73%] and 52% (41% to 66%), respectively, and the median EFS is 8.3 years ( Figure 1A ). With a median follow-up of 6.2 years (range 0.3-9.9 years) for all patients and 7.2 years in surviving patients, the actuarial OS at 5 years and 8 years after ASCT is 73% (95% CI 64% to 84%) and 63% (52% to 77%), respectively, and the median OS is 9.0 years ( Figure 1A ). The cumulative incidence of progression or relapse is shown in Figure 1B .
The estimated 5-year EFS and OS are 70% (95% CI 56% to 89%) and 84% (72% to 98%), respectively, for follicular lymphomas including transformations ( Figure 1C ); 79% (95% CI 65% to 97%) and 92% (82% to 100%) for follicular lymphomas excluding transformations; 60% (95% CI 41% to 88%) and 72% (55% to 96%) for mantle cell lymphoma; and 66% (95% CI 53% to 82%) and 78% (67% to 91%) for indolent histologies (i.e. with the exclusion of follicular grade 3, transformed, and mantle cell lymphomas). The estimated EFS original article Annals of Oncology and OS for transformed lymphomas are 40% (95% CI 19% to 95%) and 60% (36% to 99%), respectively, at both 3 years and 5 years.
Twenty-five (32%) of the 77 patients have progressed or relapsed and 28 (36%) have died. Nineteen deaths occurred in patients with progressive or relapsed disease, with a median time from relapse to death of 11 months. Of the nine nonrelapse deaths, seven were potentially transplant related as described below and two were unrelated. ASCT, autologous stem-cell transplantation; DLBCL, diffuse large B-cell lymphoma; MALT, mucosa-associated lymphoid tissue; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; TBI, total body irradiation. 
toxic effects
The median time to a sustained ANC ‡500/ll after ASCT was 11 days (range 8-19 days). The median time to a sustained platelet count ‡20 000/ll, measured at least 1 week after last platelet transfusion, was 17 days (range 10-550 days). Neutropenic fevers, mostly culture negative, occurred in 73% of the patients during the immediate posttransplantation period and were without hemodynamic compromise. One patient died of cardiac arrest 93 days after ASCT. There were six deaths beyond 100 days that were potentially transplant related. Two were from secondary hematologic cancers (MDS/AML diagnosed 4 years after ASCT with cyclophosphamide-TBI conditioning, and pre-B-cell acute lymphoblastic leukemia diagnosed >6 years after ASCT with busulfancyclophosphamide conditioning) and four were from infection: adenoviral hepatitis at 4.5 months, disseminated aspergillosis at 10 months with disseminated herpes zoster 2 months earlier, Pseudomonas sepsis at <11 months, and sepsis after immunosuppression for autologous graft-versus-host disease at 11 months. A case of mycobacterial pneumonia and bronchiolitis obliterans with organizing pneumonia at 5 months and later disseminated varicella, and a case of Pneumocystis jiroveci pneumonia at 9 months, resolved without sequelae. Following neutrophil recovery, three other patients developed and recovered from herpes zoster that was disseminated and/or required hospitalization at up to 8 months after transplantation. Following neutrophil recovery, neutropenia without apparent cause (such as infection) was documented in 33 of 77 patients (43%). This includes eight cases where timing of infection in relation to neutropenia was unclear (typically selflimited viral infections, but including the fatal infections described below) and two cases with unknown clinical context. The median onset of documented neutropenia was 3.2 months (range 0.8-10.7 months) after ASCT, with the maximum recorded grade being grade 3 in 15 patients (19%), grade 4 (ANC <500/ll) in 16 patients (21%), and grade 5 in 2 patients. Because late-onset neutropenia typically occurred after patients left Johns Hopkins, they often were not receiving intensive (weekly) laboratory monitoring. In addition, some of the events occurred beyond the time (4 months) that weekly monitoring is recommended. Thus, the exact date of onset was unknown in many of the cases. These episodes were of no or no major clinical significance except for the case of fatal fungal infection and the case of fatal Pseudomonas sepsis noted previously. In addition to these cases of idiopathic neutropenia, two patients had late grade 3 neutropenia (at 0.7 and 4.6 months, respectively) that followed infections which resolved: one a catheter infection with bacteremia and one a culture-negative sinusitis and pneumonia.
immune reconstitution
Quantitative immunoglobulins and peripheral blood lymphocyte subsets before and after ASCT are shown in Figure 2 with reference values. Posttransplantation values are reported at day 60 6 2 weeks, day 180 6 1 month, 1 year 6 2 months, and 2 years 6 2 months. For each time point, Table 2 provides the number of observed laboratory values and the number of Immunoglobulins and blood lymphocyte counts before and after transplantation. Values are at baseline, day 60 6 2 weeks, day 180 6 1 month, 1 year 6 2 months, and 2 years 6 2 months. Bars represent medians, segments represent the distance from the 25th to 75th percentile, and asterisks indicate significance for mean differences from baseline (*P < 0.05, **P < 0.01). Median values of serum immunoglobulins were normal at baseline then fell significantly on average. Recovery to normal median levels occurred by 1 year for IgA (76 mg/ml) and by 2 years for IgM (57 mg/dl). Median IgG levels at 2 years (638 mg/dl), while on average not significantly different from baseline, remained below normal.
The median absolute B-cell count was low at baseline (29/ll) per the reference range provided, likely reflecting prior rituximab. B-cell counts on average declined significantly further after ASCT (median 0/ll at days 60 and 180). B-cell counts were similar to baseline by 1 year with a low-normal median level (80/ll) and were significantly improved from baseline by 2 years with a normal median level (279/ll). The proportion of patients having an absolute B-cell count of <1 was 42/46 (91%) at day 60, 47/55 (85%) at day 180, 7/54 (13%) at 1 year, and 0/41 at 2 years.
Median CD4+ T-cell counts remained depressed at 1 year (225/ll, compared with a low baseline of 383/ll) and 2 years (332/ll). In contrast, median absolute CD8+ T-cell counts (190/ll at day 180 and 408/ll at 1 year) and median NK cell counts (127/ll at day 180 and 163/ll at 1 year) remained normal at all time points assessed.
predictors of outcome
The associations between clinical variables and transplant outcomes were examined in a post hoc analysis (Table 3) . On univariate analysis, there was a trend toward inferior EFS in patients age >50 years and in patients with transformed lymphomas. These variables were statistically significant on multivariate analysis (hazard ratio 2.22, P = 0.04 and hazard ratio 2.58, P = 0.04). No significant benefit was found to transplantation in first remission compared with transplantation upon relapse. We found no significant association between EFS and having primary induction failure, being more heavily pretreated (>10 prior chemotherapy cycles), 
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having detectable bone marrow involvement before mobilization therapy, or receiving cyclophosphamide-TBI versus busulfan-cyclophosphamide conditioning. We also found no statistically significant association between EFS and the absolute lymphocyte count, T-cell subsets, or NK cells at baseline or day 60 (day 60 data shown in Table 3 ). Of the nine patients described above who developed late serious or atypical infections, day 60 lymphocyte subsets were available in six. Day 60 absolute B-cell counts were <1/ll in these cases, as in most other patients. Of 19 measures combined of the CD3+ lymphocyte count, CD4+ T-cell count, CD8+ Tcell count, and NK cell count, 10 were below normal. One patient (who developed herpes zoster) had lymphocyte values consistently below the fifth percentile of the study group. However, in the remaining patients, all measures were greater than or equal to the 13th percentile (range 13-97) and the low values were greater than or equal to the 32nd percentile (range 32-77).
discussion
We report promising, mature results of a high-dose therapy approach incorporating pre-and posttransplantation immunotherapy for patients with low-grade or mantle cell lymphoma. This strategy resulted in durable remissions with a median EFS of >8 years. The addition of rituximab carried an acceptable safety profile and, in keeping with other series [10, 11] , did not appear to impair stem-cell mobilization or engraftment.
Rituximab has the potential to substantially improve transplant outcomes [9] and recently has been increasingly administered both before and after transplantation in an effort to reduce relapse. However, the number of published clinical trials of ASCT incorporating rituximab is relatively small, and there are few data on immune reconstitution in this setting [10, 12, 20, 21] .
Prospective studies of ASCT with rituximab have recently been published in follicular lymphoma [2, 10, 20, 22] and aggressive lymphomas [12] including mantle cell lymphoma [8, 9] . The effectiveness of rituximab as an in vivo purging agent, as assessed by the ability to render stem-cell grafts free of PCR-detectable tumor cells, has been established in multiple studies [8, 9, 20] . The impact of in vivo or in vitro purging on transplant outcomes is not known with certainty. The only published randomized trial of in vitro purging did not find a benefit but was limited by low numbers [4] . Nevertheless, it has been repeatedly recognized that the eradication of detectable residual disease from marrow or blood, regardless of how achieved, is prognostically significant [2, 23, 24] .
While rituximab generally does not cause significant hematopoietic toxicity, concern has been raised about potentially increased infectious and hematopoietic toxic effects when combined with ASCT. In addition to recurrent cytopenias, prolonged hypogammaglobulinemia and unusual late infections have been noted after ASCT incorporating rituximab [10, 12, 21, 25, 26] . Although the clinical relevance of prolonged hypogammaglobulinemia is unclear, the risk of major infections does not appear to be significantly increased [22, 26] . For example, despite low IgG levels and delayed B-cell recovery, serious infections were not observed in a prospective study of ASCT incorporating adjuvant rituximab [12] . We similarly saw delayed recovery of immunoglobulin levels and B cells in our study. Most infectious complications were manageable and although a number of atypical or late infections developed, these are not inconsistent with complications of standard myeloablative therapy.
Idiopathic late-onset neutropenia was common in this study. Late-onset neutropenia has become a recognized sequela of rituximab-containing therapy. For example, in a series of patients treated with chemotherapy plus rituximab with or without transplantation, 25% developed this toxicity at a median of 3.5 months after chemotherapy completion [27] . In studies of ASCT incorporating rituximab, its incidence has ranged from <5% to >50% [10, 12, 20] . In general, this toxicity has not translated into an excessive risk of infections, although it possibly contributed to two fatal infections in our study.
With regard to hematopoietic recovery, we did not find a statistically significant association between prolonged EFS and having higher lymphocyte counts, including T-cell and NK cell subsets, at baseline or 2 months after ASCT. Improved survival has been associated with early lymphocyte reconstitution, as measured 15 days after ASCT, and may be mediated by NK cells [19] . Although the estimated median recovery time for CD4+ T-cell counts, B-cell counts, and immunoglobulins was a year or longer, most patients did not develop serious late infections, and we did not find immune monitoring helpful in predicting the development of infectious complications.
Our EFS and OS rates compare favorably with other published studies of ASCT for low-grade non-Hodgkin's lymphoma [2] [3] [4] [5] [6] 20] . For patients with relapsed follicular lymphoma, a survival advantage with ASCT has recently been demonstrated in a randomized trial [4] . The role of ASCT as up-front therapy for follicular lymphoma has been investigated in several published, randomized phase III trials and is less clear. An EFS or progression-free survival advantage has been found in some [2, 3, 5] but not all studies [6] , without a demonstrated OS advantage [2, 5, 6] . We found no significant EFS benefit to transplantation in first remission when compared with transplantation at relapse. We also did not find convincing evidence of a plateau in the survival curve ( Figure 1C) , and further follow-up is necessary in a group of diseases with a long natural history. The timing and role of ASCT in mantle cell lymphoma is likewise a matter of debate. Although an EFS advantage with ASCT has been demonstrated in mantle cell lymphoma, the impact on OS is unproven [1] . Transformed lymphomas have carried a worse prognosis in this and some other transplant series. Nevertheless, data from our group and others [28] indicate that selected patients can enjoy durable remissions after ASCT.
Other groups have found a higher rate of secondary hematologic malignancies after ASCT and indicated that this could be due to the use of TBI or in vitro purging [5, 29, 30] . Although more than half of our patients received TBI and nearly all (94%) received in vitro purged grafts, the occurrence original article Annals of Oncology of secondary hematologic malignancies in this study is relatively low to date (two patients).
The effects of pre-or posttransplantation rituximab on disease control, survival, and safety are ultimately questions to be addressed in randomized clinical trials. Our study indicates that the incorporation of rituximab both before and after ASCT is well tolerated and effective and warrants further investigation. 
